Literature DB >> 10762153

Use of structural magnetic resonance imaging to predict who will get Alzheimer's disease.

R J Killiany1, T Gomez-Isla, M Moss, R Kikinis, T Sandor, F Jolesz, R Tanzi, K Jones, B T Hyman, M S Albert.   

Abstract

We used magnetic resonance imaging (MRI) measurements to determine whether persons in the prodromal phase of Alzheimer's disease (AD) could be accurately identified before they developed clinically diagnosed dementia. Normal subjects (n = 24) and those with mild memory difficulty (n = 79) received an MRI scan at baseline and were then followed annually for 3 years to determine which individuals subsequently met clinical criteria for AD. Patients with mild AD at baseline were also evaluated (n = 16). Nineteen of the 79 subjects with mild memory difficulty "converted" to a diagnosis of probable AD after 3 years of follow-up. Baseline MRI measures of the entorhinal cortex, the banks of the superior temporal sulcus, and the anterior cingulate were most useful in discriminating the status of the subjects on follow-up examination. The accuracy of discrimination was related to the clinical similarity between groups. One hundred percent (100%) of normal subjects and patients with mild AD could be discriminated from one another based on these MRI measures. When the normals were compared with the individuals with memory impairments who ultimately developed AD (the converters), the accuracy of discrimination was 93%, based on the MRI measures at baseline (sensitivity = 0.95; specificity = 0.90). The discrimination of the normal subjects and the individuals with mild memory problems who did not progress to the point where they met clinical criteria for probable AD over the 3 years of follow-up (the "questionables") was 85% and the discrimination of the questionables and converters was 75%. The apolipoprotein E genotype did not improve the accuracy of discrimination. The specific regions selected for each of these discriminations provides information concerning the hierarchical fashion in which the pathology of AD may affect the brain during its prodromal phase.

Entities:  

Mesh:

Year:  2000        PMID: 10762153

Source DB:  PubMed          Journal:  Ann Neurol        ISSN: 0364-5134            Impact factor:   10.422


  197 in total

1.  An automated technique for measuring hippocampal volumes from MR imaging studies.

Authors:  K M Gosche; J A Mortimer; C D Smith; W R Markesbery; D A Snowdon
Journal:  AJNR Am J Neuroradiol       Date:  2001-10       Impact factor: 3.825

2.  Prediction of cognitive decline in normal elderly subjects with 2-[(18)F]fluoro-2-deoxy-D-glucose/poitron-emission tomography (FDG/PET).

Authors:  M J de Leon; A Convit; O T Wolf; C Y Tarshish; S DeSanti; H Rusinek; W Tsui; E Kandil; A J Scherer; A Roche; A Imossi; E Thorn; M Bobinski; C Caraos; P Lesbre; D Schlyer; J Poirier; B Reisberg; J Fowler
Journal:  Proc Natl Acad Sci U S A       Date:  2001-08-28       Impact factor: 11.205

3.  Functional MRI detection of pharmacologically induced memory impairment.

Authors:  Reisa Sperling; Douglas Greve; Anders Dale; Ronald Killiany; Jennifer Holmes; H Diana Rosas; Andrew Cocchiarella; Paul Firth; Bruce Rosen; Stephen Lake; Nicholas Lange; Carol Routledge; Marilyn Albert
Journal:  Proc Natl Acad Sci U S A       Date:  2001-12-26       Impact factor: 11.205

Review 4.  Neuroimaging and behavior: probing brain behavior relationships in the 21st century.

Authors:  J Mandzia; S E Black
Journal:  Curr Neurol Neurosci Rep       Date:  2001-11       Impact factor: 5.081

5.  Detection of grey matter loss in mild Alzheimer's disease with voxel based morphometry.

Authors:  G B Frisoni; C Testa; A Zorzan; F Sabattoli; A Beltramello; H Soininen; M P Laakso
Journal:  J Neurol Neurosurg Psychiatry       Date:  2002-12       Impact factor: 10.154

6.  The Alzheimer's Disease Neuroimaging Initiative: Annual change in biomarkers and clinical outcomes.

Authors:  Laurel A Beckett; Danielle J Harvey; Anthony Gamst; Michael Donohue; John Kornak; Hao Zhang; Julie H Kuo
Journal:  Alzheimers Dement       Date:  2010-05       Impact factor: 21.566

Review 7.  Update on the biomarker core of the Alzheimer's Disease Neuroimaging Initiative subjects.

Authors:  John Q Trojanowski; Hugo Vandeerstichele; Magdalena Korecka; Christopher M Clark; Paul S Aisen; Ronald C Petersen; Kaj Blennow; Holly Soares; Adam Simon; Piotr Lewczuk; Robert Dean; Eric Siemers; William Z Potter; Michael W Weiner; Clifford R Jack; William Jagust; Arthur W Toga; Virginia M-Y Lee; Leslie M Shaw
Journal:  Alzheimers Dement       Date:  2010-05       Impact factor: 21.566

Review 8.  Alliance for aging research AD biomarkers work group: structural MRI.

Authors:  Clifford R Jack
Journal:  Neurobiol Aging       Date:  2011-12       Impact factor: 4.673

9.  Medial temporal lobe function and structure in mild cognitive impairment.

Authors:  Bradford C Dickerson; David H Salat; Julianna F Bates; Monika Atiya; Ronald J Killiany; Douglas N Greve; Anders M Dale; Chantal E Stern; Deborah Blacker; Marilyn S Albert; Reisa A Sperling
Journal:  Ann Neurol       Date:  2004-07       Impact factor: 10.422

10.  Neuropsychological prediction of conversion to dementia from questionable dementia: statistically significant but not yet clinically useful.

Authors:  J Tian; R S Bucks; J Haworth; G Wilcock
Journal:  J Neurol Neurosurg Psychiatry       Date:  2003-04       Impact factor: 10.154

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.